Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.
Maertens J, Cordonnier C, Jaksch P, Poiré X, Uknis M, Wu J, Wijatyk A, Saliba F, Witzke O, Villano S. Maertens J, et al. Among authors: saliba f. N Engl J Med. 2019 Sep 19;381(12):1136-1147. doi: 10.1056/NEJMoa1714656. N Engl J Med. 2019. PMID: 31532960 Clinical Trial.
Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial.
Winston DJ, Saliba F, Blumberg E, Abouljoud M, Garcia-Diaz JB, Goss JA, Clough L, Avery R, Limaye AP, Ericzon BG, Navasa M, Troisi RI, Chen H, Villano SA, Uknis ME; 1263-301 Clinical Study Group. Winston DJ, et al. Among authors: saliba f. Am J Transplant. 2012 Nov;12(11):3021-30. doi: 10.1111/j.1600-6143.2012.04231.x. Epub 2012 Sep 4. Am J Transplant. 2012. PMID: 22947426 Free article. Clinical Trial.
Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey.
Navarro D, San-Juan R, Manuel O, Giménez E, Fernández-Ruiz M, Hirsch HH, Grossi PA, Aguado JM; ESGICH CMV Survey Study Group, on behalf of the European Study Group of Infections in Compromised Hosts (ESGICH) from the Society of Clinical Microbiology and Infectious Diseases (ESCMID). Navarro D, et al. Transpl Infect Dis. 2017 Dec;19(6). doi: 10.1111/tid.12773. Epub 2017 Oct 25. Transpl Infect Dis. 2017. PMID: 28859257
Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study.
Fischer L, Saliba F, Kaiser GM, De Carlis L, Metselaar HJ, De Simone P, Duvoux C, Nevens F, Fung JJ, Dong G, Rauer B, Junge G; H2304 Study Group. Fischer L, et al. Among authors: saliba f. Transplantation. 2015 Jul;99(7):1455-62. doi: 10.1097/TP.0000000000000555. Transplantation. 2015. PMID: 26151607 Clinical Trial.
Use of echinocandin prophylaxis in solid organ transplantation.
Giannella M, Husain S, Saliba F, Viale P. Giannella M, et al. Among authors: saliba f. J Antimicrob Chemother. 2018 Jan 1;73(suppl_1):i51-i59. doi: 10.1093/jac/dkx449. J Antimicrob Chemother. 2018. PMID: 29304212 Review.
Early Switch From Tacrolimus to Everolimus After Liver Transplantation: Outcomes at 2 Years.
Saliba F, Duvoux C, Dharancy S, Dumortier J, Calmus Y, Gugenheim J, Kamar N, Salamé E, Neau-Cransac M, Vanlemmens C, Durand F, Pageaux G, Leroy V, Hardwigsen J, Gharbi H, Masson C, Tindel M, Conti F. Saliba F, et al. Liver Transpl. 2019 Dec;25(12):1822-1832. doi: 10.1002/lt.25664. Liver Transpl. 2019. PMID: 31631501 Free PMC article.
270 results